Complete colorblindness (achromatopsia) is caused by autosomal recessively inherited mutations in the retinal phototransduction pathway, predominantly in the CNGA3-and CNGB3-subunit of the cyclic nucleotidegated (CNG) channels in cone photoreceptors. CNGA3, which is mutated in about 25% of the achromatopsia patients, mainly harbors missense mutations which frequently impair the folding and/or trafficking of the mutant CNGA3-channels [1] .
Pharmacological chaperones stabilizing the folding of the mutant protein may be used to overcome this folding-/trafficking-deficiency. More than 50 compounds were evaluated in their ability to restore signal transduction using a calcium imaging-based bioassay utilizing the CNGA3-mutant E228K [2] . With this data we created several pharmacophore models using Schrödinger Phase [3] , which describe the chemical features of potential pharmacological chaperones targeting achromatopsia.
We used several approaches leading to different pharmacophore hypotheses: a) Training with the complete set of experimental data (see Figure 1) b) Training with only dihydropyridines since this group showed the highest experimental activity, and c) Training with a data set excluding dihydropyridines. Our in-house database TueScreen, which includes ZINC12 [4] , was screened to identify potentially active compounds. As a result, several potential molecule classes could be found that may be useful as pharmacological chaperones to improve folding/trafficking of mutant CNG-channels. We will experimentally validate these predictions in a calcium imaging-based bioassay. 
